Health Care · Pharmaceutical Preparations

ABBV AbbVie Inc SEC Filings & Insider Trading Activity 2026

company
CIK 155115297 filings
S&P 500

ABBV at a glance

AbbVie Inc (ABBV, SEC CIK 1551152) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), AbbVie Inc (ABBV) reported revenue of $61.2 billion (up 8.6% from FY2024) and net income of $4.2 billion. Diluted EPS was $2.36.
  • As of September 30, 2026, 70 institutional investment managers tracked by SignalX reported holding AbbVie Inc (ABBV) shares worth $172.9 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Stewart Jeffrey Ryan on November 9, 2026 of 40,619 shares at $293.60 per share.
  • In the last 90 days, ABBV insiders reported 0 open-market purchases ($0) and 1 open-market sale ($11.9M) on Form 4, a net sale of $11.9M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$61.2B
+8.6% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$11.9M
13F holders
70 funds
$172.9B · −3 vs prior quarter
Latest 8-K
Nov 2, 2026
Item 5.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: global biopharmaceutical company focused on innovative therapies in immunology, neuroscience, oncology, aesthetics, and eye care
  • New emphasis: expanded indications and geographic approvals for Skyrizi and Rinvoq across autoimmune diseases, plus new oncology ADC Epkinly approved for lymphoma
  • Strategic shift: single global business segment operating model aligned for unified resource allocation and long-term strategic goal achievement
  • Quantitative highlight: 2025 gross revenues in U.S. distributed mostly through three wholesalers, none exceeding 43% share
  • Noteworthy fact: continued biosimilar competition pressure on Humira globally, with evolving FDA regulatory pathway and complex approval process

Risk Factors

  • FDA approval and EC marketing authorization for Rinvoq in 2025 for giant cell arteritis and ulcerative colitis, supporting U.S. exclusivity through April 2037
  • Global minimum tax "Pillar Two" implementation starting 2024 raising future income tax expense uncertainty under OECD rules
  • Capital investment including new U.S. API facility in Illinois and biologics expansion in Massachusetts increases operational complexity and execution risk
  • Biosimilar competition driving Humira U.S. net revenues down 57% in 2025 threatens market position and revenue stability
  • $6.5B contingent consideration liabilities fair value increase in 2025 linked to Skyrizi sales projections creating significant financial risk exposure

Management Discussion & Analysis

  • Revenue $61.2B, up 9% YoY on reported and constant currency basis
  • Operating earnings $15.1B, operating margin approximately 24.7% (15.1B/61.2B)
  • Best segment: not explicitly broken down; costs include $7.4B amortization, $6.5B contingent liabilities fair value change
  • Cash flow from operations $19.0B, no disclosed buybacks or dividends, ongoing investment in pipeline and brands
  • Forward outlook: $100B pledged for US R&D/capex over decade, tariff exemption for 3 years, risk of revenue erosion from Medicare price controls starting 2026

AI summary of the ABBV 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $17,404M, up 10.3% YoY from $15,776M
  • Gross margin $13,119M, 75.4% vs 66.4% YoY
  • Best performer: Skyrizi revenue $5,776M, up 22.7%; worst: Humira, down 31.2%
  • Operating cash flow $14,871M, up from $13,812M; acquisitions used $10.6B
  • Headwinds: biosimilar competition, drug pricing reform, tariffs and global macroeconomic uncertainty

AI summary of the ABBV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 2, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Jennifer L. Davis resigning as Class II director effective November 2, 2026
  • Departure follows her appointment as Align Technology CEO
Filed Oct 30, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $17.404B, up 10.3%, with immunology up 16.3% and neuroscience up 19.4%
  • Skyrizi revenue $5.776B and Rinvoq $2.706B, both growing over 22%, offsetting Humira’s 31.2% decline

Item 2.02: Results of Operations and Financial Condition

  • AbbVie’s third-quarter 2026 financial results cover the period ended September 30, 2026
  • Detailed revenue, earnings, guidance and product performance are contained in Exhibit 99.1, the accompanying earnings release
Filed Oct 15, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded from 12 to 13 directors through appointment of Dr. John M. Carethers
  • Carethers classified independent under NYSE and AbbVie governance standards, supporting board oversight credibility

AI summaries of ABBV 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ABBV

Don't miss the next ABBV filing

  • Alerts as it files. A push when ABBV files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ABBV, by share count.
  • Ask anything. An AI agent that reads every ABBV filing and answers with sources.

ABBV alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
SALEKI AZITAFNov 16, 2026$298.55
SALEKI AZITAMNov 16, 2026$61.36
SALEKI AZITAMNov 16, 2026-
Stewart Jeffrey RyanGNov 12, 2026-
Stewart Jeffrey RyanMNov 9, 2026$114.36
Stewart Jeffrey RyanMNov 9, 2026$93.50
Stewart Jeffrey RyanSellNov 9, 2026$293.60
Stewart Jeffrey RyanMNov 9, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$56.3B$61.2B
Gross Profit-$10.7B$12.1B
Operating Income-$9.1B$15.1B
Net Income-$4.3B$4.2B
Gross Margin-19.0%19.7%
Op. Margin-16.2%24.6%
Net Margin-7.6%6.9%
Balance Sheet
Total Assets$134.7B$135.2B$134.0B
Equity$10.4B$3.3B-$3.3B
ROE-128.7%-129.2%
Per Share
EPS-$2.39$2.36
Cash Flow
Operating CF-$18.8B$19.0B
CapEx-$974.0M$1.2B

Source: XBRL data in AbbVie Inc (ABBV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ABBV share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ABBV shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202670$172.90B
Q2 202673$172.56B
Q1 202674$148.38B
Q4 202572$157.05B
Q3 202577$176.71B
Q2 202574$130.91B
Q1 202570$114.57B
Q4 202467$70.33B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 577 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ABBV filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 12, 2026--
10-QNov 3, 2026Analysis
8-KNov 2, 2026Analysis-
8-KOct 30, 2026Analysis-
8-KOct 15, 2026Analysis-
8-KOct 5, 2026Analysis-
4Oct 2, 2026--
4Oct 2, 2026--
8-KSep 3, 2026Analysis-
8-KAug 18, 2026Analysis-
4Aug 18, 2026--
8-KAug 5, 2026Analysis-
10-QAug 3, 2026Analysis
8-KJul 31, 2026Analysis-
8-KJul 6, 2026Analysis-
4Jul 2, 2026--
8-KJun 22, 2026Analysis-
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-
8-KMay 12, 2026Analysis
4May 12, 2026-
4May 12, 2026-
4May 12, 2026-

Related Health Care companies

All Health Care →

ABBV SEC filings: frequently asked questions

Are ABBV insiders buying or selling?

In the last 90 days, AbbVie Inc (ABBV) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $11.9 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ABBV stock?

As of September 30, 2026, the largest AbbVie Inc (ABBV) holders among the 13F filers tracked by SignalX were BlackRock ($39.0 billion), Vanguard Capital Management LLC ($30.3 billion), State Street Corp ($21.7 billion), Vanguard Portfolio Management LLC ($12.8 billion), JPMorgan Chase & Co ($11.9 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ABBV's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), AbbVie Inc (ABBV) reported revenue of $61.2 billion (up 8.6% from FY2024) and net income of $4.2 billion. Diluted EPS was $2.36. The figures come from the XBRL data in the 10-K.

What are the main risks in ABBV's latest 10-K?

In the 10-K filed February 20, 2026, AbbVie Inc (ABBV) flagged: FDA approval and EC marketing authorization for Rinvoq in 2025 for giant cell arteritis and ulcerative colitis, supporting U.S. exclusivity through April 2037. Global minimum tax "Pillar Two" implementation starting 2024 raising future income tax expense uncertainty under OECD rules. (AI summary of the Risk Factors section.)

What did ABBV report in its latest 8-K?

AbbVie Inc (ABBV) filed an 8-K on November 2, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Jennifer L. Davis resigning as Class II director effective November 2, 2026.

What are the latest ABBV SEC filings?

AbbVie Inc (ABBV) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 18, 2026.

What is ABBV's SEC CIK number?

AbbVie Inc (ABBV)'s SEC Central Index Key (CIK) is 1551152. EDGAR lists every ABBV filing under that number.

Ask anything about ABBV

The research agent reads ABBV's filings, financials, insider trades and 13F holders, then answers with sources.